La cadena de opciones muestra datos clave de las opciones de acciones de NextPlat a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para NextPlat..

NextPlat (NASDAQ:NXPL) Bolsa, Cadena de Opciones

NextPlat

NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

NextPlat Corp

<a href="https://www.globenewswire.com/Tracker?data=kVc1PX3ewLfFwoYWkpegoq62-6i9h7Yk8jIa5p-aCoDgF8lczPlR80cznENh7oSlbus1bV9gxtWEilYdt6RjVcQDNvcZyXbcGBug7rriDqOJvbYN-lFLVl1YLZES4z5fcjrPNO5-NJSRtwFH1CiIrbvUs8j1fDDiNCetjeLhZGY=">PolyPid Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced positive topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100&nbsp;for the prevention of SSIs in patients undergoing abdominal colorectal surgery with large incisions, which has received Fast Track designation from the FDA.
"The positive results of our Phase 3 pivotal trial provide clear and compelling evidence of D-PLEX100's ability to significantly reduce SSIs, a major burden on patients and healthcare systems, while improving clinical outcomes for both patients and physicians," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "D-PLEX100 has the potential to meaningfully lower costs for hospitals and payers, and we believe it will be a valuable addition to the standard of care. Targeting a total addressable U.S. market of over 12 million annual surgeries and a significant unmet need, D-PLEX100 has the potential to make a substantial market impact. We remain on track for an NDA submission in early 2026 and believe these robust data will serve as a strong catalyst for advancing our global partnership discussions. We are deeply grateful to the patients, principal investigators, and study teams who made this milestone possible."
Key findings from SHIELD II study include:
<ul>
<li>The primary efficacy endpoint of the study was successfully met, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p&lt;0.005). The primary endpoint is the combination of deep and superficial SSIs, all-cause mortality and surgical reinterventions at the same incision of the original index surgery. &nbsp;</li>
<li>SHIELD II included three key secondary endpoints: 
<ul>
<li>The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p&lt;0.005). &nbsp;</li>
<li>The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p&lt;0.005). This efficacy endpoint combined SSI, mortality and reintervention as evaluated in the primary endpoint. This endpoint was assessed in the overall study population of 975 patients with an incision ≥7 cm, including laparoscopic surgery patients enrolled prior to the 2023 trial protocol change. &nbsp;</li>
<li>The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1&nbsp;score &gt;20 in D-PLEX100 plus SoC arm compared to SoC alone arm (p&lt;0.05). The ASEPSIS score is a clinical tool used to objectively assess surgical wound infections. &nbsp;</li>
</ul>
</li>
<li>There were no safety concerns raised by the independent Data Safety Monitoring Board in SHIELD II.</li>
</ul>

News

PYPD

PolyPid's Surgery Drug Cuts Infection Risk by 38% in Major Phase 3 Trial

Crypto markets opened the week on on Mondya morning, buoyed by <a href="https://www.benzinga.com/markets/ipos/25/06/45819104/cathie-wood-calls-circles-ipo-an-amazing-debut">Circle's IPO success</a>, which has rekindled optimism in the broader crypto sector. The move also sparks anticipation for more public listings from major crypto firms like Gemini, Kraken and Chainalysis.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,327.87</td>
<td>+1.7%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,532.52 </td>
<td>+1%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$155.28</td>
<td>+4.1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.26</td>
<td>+1.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1853</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001267</td>
<td>+1.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume decreased by 2.4% and 1% respectively. Daily active addresses are down by 5% and 1.7% each in a single day. BTC's exchange netflows are up by 179.3%.</li>
<li>Coinglass data shows 57,771 traders were liquidated in the past 24 hours for $133.66 million.</li>
<li>SoSoValue data shows net outflows of $47.8 million into spot Bitcoin ETFs. Spot Ethereum ETFs saw net inflows of $25.2 million.</li>
</ul>
Trader Notes: Crypto analyst Kevin <a href="https://x.com/Kev_Capital_TA/status/1931866716352770230">revealed</a> he's been on the sidelines after taking profits on altcoins last month, citing the past four weeks of "truly diabolical" and unprecedented volatility in the crypto market. He remains cautious, awaiting more stable setups.
Meanwhile, trader Jelle <a href="https://x.com/CryptoJelleNL/status/1931984820072018033">remains</a> bullish, noting that global money supply is expanding, which he believes will drag Bitcoin higher, targeting $140,000. Technical analyst Ali Martinez emphasized a critical level: Bitcoin needs a confirmed close above $106,900 to validate further upside. If rejected, BTC could fall back toward $105,000 or even $103,500.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wait for a sustained close above $106,900 before you turn bullish on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> because a rejection here could send it back to $105,000 or even $103,500. <a href="https://t.co/ojwWu7pKdG">pic.twitter.com/ojwWu7pKdG</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1932015913634533616?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to More Crypto Online, SOL <a href="https://x.com/Morecryptoonl/status/1932017332743725538">remains</a> bullish as long as the $143.95–$148.28 support zone holds. A rebound from this level could kick off the next leg higher.
Trader Wolf <a href="https://x.com/IamCryptoWolf/status/1932000494207062421">believes</a> ETH is in a healthy consolidation phase following May's strong rally. A final sweep of the lows could still occur before a move higher resumes.
Analyst Kamran Ashgar highlights an ascending broadening wedge pattern. If DOGE breaks out above $0.47, it could rally toward the $3.80 textbook target.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> maintains a strong structure within an Ascending Broadening Wedge &#x1f525; The target remains 3.8 as the pattern target.&#x1f680;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/cak0hcX1IJ">pic.twitter.com/cak0hcX1IJ</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Start The Week Green Ahead Of US-China Trade Talks

Patent issuance expands United States patent coverage for AVERSA&#x2122; transdermal abuse deterrent technology
AVERSA&#x2122; transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRBW#NASDAQ">NTRBW</a>), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled "Abuse and Misuse Deterrent Transdermal Systems." The issuance of this patent further expands Nutriband's intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa&#x2122; abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA&#x2122; abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband's lead product under development is Aversa&#x2122; Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first abuse deterrent pain patch on the market with peak annual US sales estimated to be$80 million to $200 million.

NTRB

NTRBW

Nutriband Says Patent Issuance Expands US Patent Coverage For AVERSA Transdermal Abuse Deterrent Technology

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) with a Buy rating and announces Price Target of $4.

Price Target

Initiation

Analyst Ratings

MBRX

HC Wainwright & Co. Assumes Moleculin Biotech at Buy, Announces Price Target of $4

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of&nbsp;DNA pol IIIC inhibitors
LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date
Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA
STATEN ISLAND,&nbsp;N.Y., June 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its&nbsp;lead&nbsp;antibiotic&nbsp;candidate,&nbsp;ibezapolstat (IBZ), is&nbsp;ready&nbsp;to&nbsp;advance to&nbsp;international&nbsp;pivotal Phase&nbsp;3 clinical&nbsp;trials&nbsp;for treatment of&nbsp;patients&nbsp;with&nbsp;C.&nbsp;difficile&nbsp;infection&nbsp;(CDI).
The&nbsp;Company today&nbsp;announced that a presentation of a poster and an oral presentation regarding Acurx's overall DNA pol IIIC inhibitor platform was presented at a scientific conference on May 21 by Mia Urem, PhD, from Leiden University Medical Center in the Netherlands entitled: "A Unique Inhibitor Conformation Selectively Targets the DNA Polymerase PolC of Gram-Positive Priority Pathogens".&nbsp; This scientific conference is sponsored by the Federation of American Societies for Experimental Biology and is the premier venue for the newest research and technological trends in molecular "machines" inside the human body that ensure DNA replication and expression of genes to create proteins that make up a cell. The distinctive non-planar conformation of ACX-801 and IBZ, together with high conservation of the induced binding pocket in PolC, suggests that this is a general mechanism for this class of inhibitor and is conserved in Gram-positive bacteria.

ACXP

Acurx Pharma Says Lead Antibiotic Candidate, Ibezapolstat, Is Ready To Advance To International Pivotal Phase 3 Clinical Trials For Treatment Of Patients With C. Difficile Infection

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy rating and announces Price Target of $6.

HRTX

HC Wainwright & Co. Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $6

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $20 price target.

Reiteration

PHAT

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $20 Price Target

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Outbrain Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>), which is operating under the new Teads brand following Outbrain's acquisition of Teads in February 2025, announced today that the combined company has completed its corporate renaming from "Outbrain Inc." to "Teads Holding Co." The combined company will begin trading under the new ticker symbol "TEAD" on the Nasdaq effective June 10, 2025.
The change will not impact current stockholders, contracts, or operations. No action is required by shareholders in connection with the name change.

Outbrain Completes Name Change to Teads Holding Co., To Begin Trading Under New Nasdaq Symbol 'TEAD' Effective June 10

ONDS

Ondas Lands $14.3M Optimus System Order From Major Defense Customer, Largest To Date

Oddity Finance Announces $350M Offering Of 0% Exchangeable Senior Notes Due 2030

Origin Agritech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the successful hosting of its Huanghuai Region Core Customer Symposium in Zhengzhou, Henan Province, where the Company showcased nearly 300 new corn varieties and strengthened strategic relationships with core distributors across the region.
The Symposium featured comprehensive demonstrations of Origin's new variety developments, bringing together the Company's executive leadership with key customer representatives to foster deeper market integration and facilitate technology adoption.
The Field Demonstration highlights included:
<ul>
<li>Introduction of flagship corn varieties including Jinqiao 8, Jingke 317, Jundan 203, and Aoyu 728</li>
<li>Demonstration of 16 advanced validation-stage varieties with significant market potential</li>
<li>Showcase of breakthrough gene editing varieties and transgenic breeding technologies</li>
<li>Display of collaborative varieties developed with leading agricultural scientists from prestigious institutions</li>
</ul>
The event was attended by Origin's senior leadership team, including Weibin Yan, CEO &amp; Director, Yubiao Liu, Director and Vice President, Dezhi Deng, Head of Research &amp; Development, Jing Dou, Assistant President, and Kang Deng, Chairman of Henan Aoyu.
During the Symposium, Mr. Yan presented the Company's strategic vision, research achievements, and future development roadmap, engaging in detailed discussions with customers about industry trends and competitive dynamics in the corn seed market.
"This Symposium represents a significant milestone in Origin Agritech's commitment to advancing agricultural innovation in China," said Mr. Yan. "By showcasing our extensive portfolio of new varieties and biotechnology products to our core distributor network, we are accelerating market adoption while gathering valuable feedback that will guide our future research and development efforts."
The exhibition field featured dedicated zones for biotechnology product displays, cooperative expert varieties, and Origin's self-developed varieties. Participants received expert guidance on variety characteristics, cultivation management, pest control strategies, and supporting planting technologies.
The biotechnology zone highlighted Origin's genetically modified and gene-edited varieties, demonstrating the Company's innovative breakthroughs in agricultural biotechnology with significant applications for national food security and high-quality agricultural development.
The cooperative expert variety zone featured corn varieties developed in collaboration with renowned scientists including Academician Jingrui Dai from China Agricultural University, Researcher Jiuran Zhao and Yuandong Wang from Beijing Academy of Agriculture and Forestry Sciences, Professor Yuling Li and Yanhui Chen from Henan Agricultural University.
"The enthusiastic response from our distributor network confirms the market potential of our innovative seed varieties," commented Dezhi Deng, Vice President and Director of R&amp;D at Origin Agritech. "This Symposium has strengthened our market position and laid a solid foundation for the commercial launch of our next generation of corn varieties, ultimately contributing to the modernization of China's agricultural sector."

SEED

Origin Agritech Showcases 300 New Corn Varieties to Strengthen Ties With Distributors in China

Village Farms Regains Nasdaq Compliance With $1.00 Bid Price Rule

<ul>
<li>Largest demonstration of its kind combines leading hardware, platforms, and techniques to achieve 20 times speedup over previous demonstrations</li>
<li>Ecosystem collaboration marks significant step toward designing more efficient ways of producing pharmaceuticals</li>
<li>IonQ will showcase demonstration at ISC High Performance conference in Hamburg, Germany</li>
</ul>

AMZN

IONQ

NVDA

IonQ, AstraZeneca, AWS, And NVIDIA Demonstrate 20x Speedup In Quantum-Accelerated Drug Development Workflow

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL&#x2122;, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia&#x2122;, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline.
Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL&#x2122; micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space.
A New Standard in Evidence-Based Supplementation
Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL&#x2122;, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL&#x2122; is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease.
Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization.
Strategic Synergy with Core Pipeline
The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030.
The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model.

JUNS

Jupiter Neurosciences Commercially Launches Nugevia; First Consumer Products Roll Out In Q3 2025

Citadel founder and CEO Ken Griffin slammed the Trump administration for pushing the economy towards a stagflation scenario.  
What Happened: Asked about the GOP reconciliation bill at the Forbes Iconoclast Summit on Thursday, Griffin observed that "there&#8217;s a lot of question marks in the bill" and asked why the US is "continuing to increase our tax cuts when we have a fiscal deficit of this magnitude."
At present, federal debt stands at $36.21 trillion, according to data from the Treasury department.
Commenting on the current economic landscape, Griffin said, "It would be a textbook stagflation scenario. The question is, is it for several quarters, or does it become for several years?"
He also flagged the potential long-term effects of Trump's tariffs and reshoring initiatives. "The question is, is the shock from the tariff policies one time in nature, or will the scramble to build manufacturing America put us into a wage growth spiral for years to come?" Griffin asked. "That we don't know the answer to, but that is a real risk in the current environment."
Last month, <a href="https://www.benzinga.com/markets/25/05/45333895/gop-megadonor-ken-griffin-warns-trump-tariffs-are-terrifying-says-government-is-picking-winners-and-losers-amid-soaring-trade-deficit">Griffin criticized the tariff policies</a> for unleashing "an era of crony capitalism" where the government chooses "winners and losers" in the economy.
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45832237/trumps-tax-bill-will-harm-middle-class-families-warns-thomas-massie-calls-treasury-secretary-scott-bessents-4-trillion-tax-hike-claim-misleading">Trump&#8217;s Tax Bill Will Harm Middle Class Families, Warns Thomas Massie, Calls Treasury Secretary Scott Bessent&#8217;s $4 Trillion Tax Hike Claim Misleading</a>
Why It Matters: The hedge fund billionaire went on to express skepticism about the Trump administration's <a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">push towards domestic manufacturing</a> of "low value-added products." "There's no money in it for anybody, and there's certainly no money for people who are doing those jobs," he said, highlighting that <a href="https://www.benzinga.com/personal-finance/25/05/45600424/trumps-commerce-secretary-says-future-of-american-manufacturing-is-tradecraft-jobs-that-only-require-high-school-education-great-jobs-that-start-in-80000">these jobs</a>, typically abundant in China, are now moving to "lower value jurisdictions."
"Why are we aspiring to be the nation of the lowest cost and lowest paid workforce in the world? That makes no sense to me," he added, backing domestic manufacturing of "high value-added products" and "particular products that are important to our national defense."
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Billionaire Ken Griffin Slams Trump's Tax Bill, Tariffs And The $36 Trillion Debt Crisis" width="500" height="281" src="https://www.youtube.com/embed/cA-nEuVqK0Q?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45831188/gavin-newsom-to-sue-trump-administration-over-national-guard-deployment-dares-border-czar-homan-to-arrest-him">Gavin Newsom To Sue Trump Administration Over National Guard Deployment, Dares Border Czar Homan To &#8216;Arrest&#8217; Him</a></li>
</ul>
Photo courtesy: Joey Sussman / Shutterstock.com

Politics

Ken Griffin Slams Trump For Chasing Tax Cuts And Low-Wage Manufacturing, Questions Push Toward 'Lowest Paid Workforce In The World'

Enhanced Strategic Focus and Flexibility Will Better Position Storied Brands Across Entertainment, Sports and News to Drive Shareholder Value

Warner Bros. Discovery To Split Into Two Public Companies: Streaming & Studios And Global Networks In Tax-Free Transaction

Biotech

Health Care

General

INAB

IN8Bio Announced That A Patient, With A Grade 4 IDH-mutant Glioma, In A Phase 1 Trial, Has Been In Remission And Surviving For 4 Years, Having Been Treated With INB-200

<ul>
<li>$2.16 billion acquisition of Sundyne expands Honeywell's ESS product portfolio and aftermarket services, integrating critical equipment with automation and control systems powered by Honeywell Forge</li>
<li>Sundyne brings approximately 1,000 skilled employees and significant aftermarket revenue generated from a large installed base</li>
<li>Honeywell's global reach and strong customer relationships help accelerate market access and adoption of Sundyne's specialized products and services</li>
</ul>
CHARLOTTE, N.C., June 9, 2025 /PRNewswire/ -- Honeywell&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) today announced the completion of its acquisition of Sundyne from private equity firm Warburg Pincus for $2.16 billion in an all-cash transaction. The acquisition of Sundyne—a leader in the design, manufacturing, and aftermarket support of highly-engineered pumps and gas compressors for process industries—is expected to be immediately accretive to Honeywell's sales growth and segment margins as well as to adjusted EPS in the first full year of ownership.

Honeywell Completes Acquisition Of Sundyne From Private Equity Firm Warburg Pincus For $2.16B In All-Cash Transaction

HA Sustainable Infrastructure Capital, Inc. ("HASI") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>), a leading investor in sustainable infrastructure assets, and KKR, a leading global investment firm, today announced that CarbonCount Holdings 1 LLC ("CCH1"), a co-investment vehicle between HASI and KKR, has agreed to issue $592 million in aggregate principal amount of senior unsecured notes (the "Notes") in a private offering. The fixed-rate amortizing notes will have a 20-year final maturity. The Notes were priced at a weighted average coupon of 6.76%.

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HASI and KKR Team Up to Raise $592M Through 20-Year Sustainable Infrastructure Bond Deal

Press Releases

NextPlat Changes the Date of its 2024 Financial Results Report and Investor Conference Call to Monday, March 24, 2025

Earnings

NextPlat Reports $65.5 Million in Consolidated Year-End 2024 Revenue

Contracts

NextPlat's Global Telesat Awarded New UK Government Contract for Iridium Extreme® Push to Talk Devices

NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

NextPlat's Global Telesat Receives Connectivity Services Contract Extension from Military Customer

NextPlat Corp Receives Nasdaq Notification Regarding Minimum Bid Requirements

NextPlat to Release First Quarter 2025 Results on Thursday, May 15, 2025

NextPlat Reports First Quarter 2025 Results

NextPlat's Global Telesat Named Exclusive UK and EU Distributor for ZOLEO Satellite Communicators, Further Expanding its Global Network of Connectivity Solution Partnerships

NextPlat Issues Statement on the Passing of its Executive Chairman and CEO Charles M. Fernandez

NXPL

AST SpaceMobile, Inc. - Class A Common Stock

AST SpaceMobile

Anterix

Bandwidth

Cogent Communications Holdings, Inc. - Common Stock

Cogent Comms Hldgs

Globalstar

iOThree

iQSTEL

Iridium Communications Inc - Common Stock

Iridium Communications

Liberty Global Ltd. - Class A Common Shares

Liberty Global

Liberty Global Ltd. - Class C Common Shares

Liberty Latin America Ltd. - Class A Common Stock

Liberty Latin America

Liberty Latin America Ltd. - Class C Common Stock

Lumen Technologies

Sify Technologies Limited - American Depository Shares, each represented by one Equity Share

Comments

NextPlat

NextPlat (NXPL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL